Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Raised to $40.00

Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by Wedbush from $23.00 to $40.00 in a research report sent to investors on Monday, MarketBeat Ratings reports. Wedbush currently has an outperform rating on the stock.

A number of other equities analysts have also recently commented on ARTV. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a report on Monday, May 4th. Wall Street Zen upgraded Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, HC Wainwright raised their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock opened at $10.50 on Monday. The business has a 50-day moving average of $8.00 and a 200 day moving average of $5.52. Artiva Biotherapeutics has a 12 month low of $1.47 and a 12 month high of $14.53. The stock has a market capitalization of $259.56 million, a price-to-earnings ratio of -2.97 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities research analysts anticipate that Artiva Biotherapeutics will post -2.8 earnings per share for the current year.

Insider Activity

In related news, Director Ra Capital Management, L.P. acquired 6,510,416 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $11.52 per share, for a total transaction of $74,999,992.32. Following the purchase, the director owned 15,203,995 shares of the company’s stock, valued at $175,150,022.40. This represents a 74.89% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 21.40% of the company’s stock.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ARTV. Citadel Advisors LLC boosted its stake in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares during the period. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics during the 4th quarter worth about $341,000. Jane Street Group LLC acquired a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth about $67,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $112,000.

More Artiva Biotherapeutics News

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Ra Capital Management disclosed a purchase of 6.51 million shares at $11.52 each, a roughly $75 million insider buy that materially increased its stake in Artiva Biotherapeutics. SEC Form 4 filing
• Positive Sentiment: Needham & Company raised its price target on Artiva Biotherapeutics to $41 from $18 and kept a buy rating, implying substantial upside from current levels. Benzinga report
• Positive Sentiment: HC Wainwright reiterated a buy rating and $35 price target while raising several earnings estimates for 2026 and beyond, suggesting improving expectations for the company’s long-term earnings path.
• Positive Sentiment: Additional analyst updates from Cantor Fitzgerald and Wedbush were also described as positive, reinforcing the broader bullish sentiment around ARTV.
• Neutral Sentiment: Some HC Wainwright estimates were mixed, with certain long-term EPS forecasts lowered even as nearer-term projections improved, so the analyst picture is not uniformly optimistic.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.